Rejuvenate Bio
San Diego, US · Delaware corporation · 5 known investors
Rejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer. It targets both companion animals (particularly dogs) and humans.
Founders & leadership
ND
Noah DavidsohnCSO, Co-Founder
DO
Daniel OliverCEO, Co-Founder
GC
George ChurchCo-Founder and SAB
DA
Deborah AscheimChief Medical Officer
Board
Investors · 5
Reported raises · per SEC filings
Form D private placements$34M disclosed across 2 rounds · 2021–2026
▶$19.5MraisedJun 2026 · 35 investors · BiotechnologyRule 506(b)
▶$19.5MraisedJun 2026 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Noah DavidsohnExecutive Officer, Director
- David ZhuDirector
- Daniel OliverExecutive Officer, Director
- Offering amount
- $27M
- Amount sold
- $19.5M
- Minimum investment
- $20K
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.6MraisedApr 2021 · 22 investors · BiotechnologyRule 506(b)
▶$14.6MraisedApr 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel OliverExecutive Officer, Director
- Noah DavidsohnExecutive Officer, Director
- Offering amount
- $15.3M
- Amount sold
- $14.6M
- Minimum investment
- $10K
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapLife Biosciences18 shared keywordsLongevity company with diversified therapies to extend healthy human lifespan
Lifespan15 shared keywordsLifespan.io publishes news, research roundups, and advocacy content focused on longevity and rejuvenation therapies aimed at extending healthy lifespan. It covers developments across research, treatment, and policy related to aging.
bio12 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
Rejuvenation Technologies Inc.10 shared keywordsRejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.
Regeneron NASDAQ: REGN www.regeneron.com9 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Companies competing with Rejuvenate Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseSpecial Operations Command | Phase II | 2022 | $3M |
| Department of DefenseSpecial Operations Command | Phase IISTTR | 2021 | $2.1M |
| Department of DefenseSpecial Operations Command | Phase II | 2020 | $1.4M |
| Department of DefenseSpecial Operations Command | Phase IISTTR | 2019 | $1.4M |
| Department of DefenseSpecial Operations Command | Phase II | 2018 | $1.4M |
| Department of DefenseSpecial Operations Command | Phase I | 2018 | $150K |
| Department of DefenseSpecial Operations Command | Phase ISTTR | 2018 | $149.9K |
| Department of DefenseSpecial Operations Command | Phase I | 2018 | $99.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Rejuvenate Bio has filed a notice of an exempt offering of securities to raise $27,049,354.00 in New Funding. - intelligence360intelligence360.news · Jul 2026
Rejuvenate Bio Raises $6M in Financingfinsmes.com · Jun 2026Frequently asked questions
- What does Rejuvenate Bio do?
- Rejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer. It targets both companion animals (particularly dogs) and humans.
- Who founded Rejuvenate Bio?
- Rejuvenate Bio was founded by Noah Davidsohn, Daniel Oliver, George Church.
- Who are Rejuvenate Bio's investors?
- Rejuvenate Bio's investors include Companion Fund, Connecticut Innovations, Digitalis Ventures, Kendall Capital Partners, KdT Ventures.
- How much funding has Rejuvenate Bio raised?
- Rejuvenate Bio has disclosed $34M raised across 2 rounds.
- Where is Rejuvenate Bio headquartered?
- Rejuvenate Bio is headquartered in San Diego, US.